2019 WGND Annual Meeting

October 29, 2019 | Hyderabad, India

Overview

The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.

Speakers
Melvin Spigelman
TB Alliance, WGND
Barbara Laughon
NIH/NIAID, WGND
Gavin Churchyard
AIDS Clinical Trials Group
Payam Nahid
Centers for Disease Control / TB Trials Consortium
Charles Wells
Gates Medical Research Institute
Joel Lilievre
GSK
Tine DeMarez
Janssen
Anil Koul
Johnson & Johnson
Marc Destito
Otsuka
Kiyean Nam
Qurient
Andreas Diacon
Stellenbosch University
Andreas Diacon
Stellenbosch University
Eugene Sun
TB Alliance
Michael Hoelscher
EDCTP/University of Munich
Nicholas Paton
Meeting Recap

The 2019 WGND Annual Meeting and Reception took place on Tuesday, October 29th from 16:00 to 20:00 IST in the Pearl 3 Room at the Cyber Convention Centre. The meeting occurred in conjunction with the 50th Union World Conference on Lung Health in Hyderabad, India. During the meeting, updates were provided by representatives from: 

  • AIDS Clinical Trial Group
  • US Centers for Disease Control / TB Trials Consortium
  • Gates Medical Research Institute
  • GlaxoSmithKline
  • Janssen / Johnson & Johnson
  • Ludwig-Maximilians University / PanACEA
  • Otsuka Pharmaceuticals
  • Qurient
  • TASK Applied Science / Stellenbosch University
  • TB Alliance
  • TB Drug Pipeline Updates
    TB Drug Development Year-in-Review
    Barbara Laughon
    https://www.newtbdrugs.org/sites/default/files/meetings/files/01_Year-in-Review_Barbara%20Laughon.pdf
    AIDS Clinical Trials Group
    Gavin Churchyard
    https://www.newtbdrugs.org/sites/default/files/meetings/files/02_AIDS%20Clinical%20Trial%20Group_Gavin%20Churchyard.pdf
    Centers for Disease Control / TB Trials Consortium
    Payam Nahid
    https://www.newtbdrugs.org/sites/default/files/meetings/files/03_CDC_TBTC_Payam%20Nahid%2012.18.2019.pdf
    Gates Medical Research Institute
    Charles Wells
    https://www.newtbdrugs.org/sites/default/files/meetings/files/04_Gates%20MRI_Charles%20Wells.pdf
    GlaxoSmithKline
    David Barros
    Janssen
    Tine DeMarez
    https://www.newtbdrugs.org/sites/default/files/meetings/files/06_Janssen_Tine%20De%20Marez.pdf
    Johnson & Johnson
    Anil Koul
    Otsuka
    Marc Destito
    https://www.newtbdrugs.org/sites/default/files/meetings/files/09_Otsuka_Marc%20Destito_updated.pdf
    Qurient, Inc.
    Andreas Diacon
    TASK Applied Science / Stellenbosch University
    Andreas Diacon
    TB Alliance
    Eugene Sun
    https://www.newtbdrugs.org/sites/default/files/meetings/files/12_TB%20Alliance_Eugene%20Sun.pdf
    University of Munich / PanACEA
    Michael Hoelscher
    https://www.newtbdrugs.org/sites/default/files/meetings/files/08_LMU-PanACEA_Michael%20Hoelscher-NHeinrich.pdf
    SPRINT TB
    Nicholas Paton
    https://www.newtbdrugs.org/sites/default/files/meetings/files/12b_NUSingapore_Nick%20Paton.pdf